Fosun Pharma Reports Earnings Growth Driven by Global Innovation

Innovation remains the primary lever for the company, with revenue from innovative drugs climbing 13.84% to RMB 4.911 billion. This segment now accounts for over a third of total pharmaceutical revenue. R&D spending surged 25.66% to RMB 3.247 billion, with more than 80% of those funds directed toward oncology, immunology, and neurodegenerative disease pipelines. During the reporting period, the company secured approvals for 20 new indications across seven products, strengthening its competitive footprint in solid tumor treatments like lung and breast cancer.

Fosun Pharma is also accelerating its international strategy, with revenue from outside the Chinese mainland growing 16.45% to RMB 6.379 billion. The company is moving beyond simple exports toward a system-level global deployment. Partnerships with firms like Eisai and Abbott for the drug serplulimab exemplify this approach, extending the reach of domestic innovations into markets across Europe, Asia, and the Middle East. Meanwhile, the company’s manufacturing arm, Gland Pharma, continues to leverage its U.S. FDA-approved facilities to secure supply agreements for complex sterile injectables. Chairman Chen Yuqing noted that the company is responding to external market uncertainties by doubling down on its long-term commitment to clinical-value-driven development and global commercialization.